Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:2)
2. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrochloride (1:1)
3. E 7438
4. E-7438 Hydrobromide
5. E7438
6. Epz-6438
7. Epz-6438 Dihydrobromide
8. Epz-6438 Monohydrobromide
9. Epz-6438 Monohydrochloride
10. Epz-6438 Trihydrochloride
11. Ez-438
12. Ez438
13. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide
14. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide
15. Tazemetostat
16. Tazemetostat Dihydrobromide
17. Tazemetostat Hydrochloride
18. Tazemetostat Monohydrobromide
19. Tazemetostat Monohydrochloride
20. Tazemetostat Trihydrochloride
21. Tazverik
1. 1467052-75-0
2. Tazemetostat Monohydrobromide
3. Epz-6438 Monohydrobromide
4. E-7438 Hydrobromide
5. Ez438
6. Tazemetostat (hydrobromide)
7. Epz-6438 Hydrobromide
8. Tazemetostat Hydrobromide [usan]
9. Tazverik
10. Ez-438
11. 6p89t5m073
12. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:1)
13. N-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide
14. Unii-6p89t5m073
15. Tazverik (tn)
16. 1467052-77-2
17. Chembl4594260
18. Schembl15313373
19. Dtxsid101027715
20. Hy-13803c
21. Tazemetostat Hydrobromide (jan/usan)
22. Tazemetostat Hydrobromide [jan]
23. Tazemetostat Hydrobromide [who-dd]
24. Epz-6438 Hydrobromide; Tazemetostat Hbr
25. Cs-0101826
26. D11485
27. Tazemetostat Hydrobromide [orange Book]
28. Q27265267
29. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide
30. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide Hydrobromide
31. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamidehydrobromide
Molecular Weight | 653.6 g/mol |
---|---|
Molecular Formula | C34H45BrN4O4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 9 |
Exact Mass | 652.26242 g/mol |
Monoisotopic Mass | 652.26242 g/mol |
Topological Polar Surface Area | 83.1 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 992 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Tazemetostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tazemetostat, including repackagers and relabelers. The FDA regulates Tazemetostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tazemetostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tazemetostat supplier is an individual or a company that provides Tazemetostat active pharmaceutical ingredient (API) or Tazemetostat finished formulations upon request. The Tazemetostat suppliers may include Tazemetostat API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tazemetostat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tazemetostat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tazemetostat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tazemetostat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tazemetostat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tazemetostat suppliers with NDC on PharmaCompass.
Tazemetostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tazemetostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tazemetostat GMP manufacturer or Tazemetostat GMP API supplier for your needs.
A Tazemetostat CoA (Certificate of Analysis) is a formal document that attests to Tazemetostat's compliance with Tazemetostat specifications and serves as a tool for batch-level quality control.
Tazemetostat CoA mostly includes findings from lab analyses of a specific batch. For each Tazemetostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tazemetostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Tazemetostat EP), Tazemetostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tazemetostat USP).
LOOKING FOR A SUPPLIER?